Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

241.60 -5.31 (-2.15%)
Streaming Delayed Price Updated: 10:43 AM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,447,977
Open 246.47
Bid (Size) 241.51 (500)
Ask (Size) 241.70 (300)
Prev. Close 246.91
Today's Range 240.28 - 246.88
52wk Range 141.50 - 246.96
Shares Outstanding 2,628,679,824
Dividend Yield 2.15%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Friday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
News headline image
JNJ Stock Rises As Drugmaker Reportedly Eyes Orthopedics Segment Sale For Up To $20B ↗
Bloomberg reported, citing people familiar with the matter, that DePuy Synthes could be valued at more than $20 billion in a sale. 
Via Stocktwits

Performance

YTD
+16.5%
+16.5%
1 Month
+10.7%
+10.7%
3 Month
+19.0%
+19.0%
6 Month
+35.0%
+35.0%
1 Year
+53.0%
+53.0%

More News

Read More
News headline image
Health Care Sector (XLV) Shows Resilience Amid Tech Volatility and Strong Jobs Data
Via MarketMinute
Topics Artificial Intelligence ETFs Earnings
News headline image
Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
From Johnson & Johnson
Via Business Wire
Johnson & Johnson (NYSE:JNJ) Stands Out as a High-Quality Dividend Aristocrat for Income Investors ↗
Via Chartmill
News headline image
FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer ↗
Via Benzinga
News headline image
Behind the Scenes of Johnson & Johnson's Latest Options Trends ↗
Via Benzinga
News headline image
Johnson & Johnson's New FDA Approval Lets Lung Cancer Patients Switch To Monthly Dosing Sooner ↗
Via Benzinga
News headline image
The Seven-Thousand Siege: S&P 500’s Historic Breach and the Great Tech Pivot of 2026
Via MarketMinute
Topics Artificial Intelligence ETFs Earnings
News headline image
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
From BioMedWire
Via GlobeNewswire
News headline image
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
Via MarketMinute
Topics Intellectual Property
News headline image
Jury: Johnson & Johnson Liabile in Case Linking Baby Powder to Cancer ↗
Via Benzinga
News headline image
Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial
From Beasley Allen Law Firm
Via Business Wire
News headline image
Volatility Returns to Wall Street: VIX Surges 18% as AI Fatigue Triggers Massive Three-Day Sector Rotation
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
"Blowout" Jobs Report Ignites 2026 Growth Hopes as Unemployment Hits 4.3% Floor
Via MarketMinute
Topics Artificial Intelligence Economy Workforce
News headline image
The Great Rebound: US M&A Market Ignites as Megadeals Surge 111% in AI-Driven Supercycle
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Is Johnson & Johnson a Buy, Sell, or Hold in 2026? ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property Lawsuit
News headline image
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
Via FinancialNewsMedia
News headline image
Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
News headline image
5 Stocks and ETFs to Help Shield Your Portfolio During Volatility ↗
Via MarketBeat
Topics ETFs
News headline image
Johnson & Johnson Reports 90% AFib Freedom In Early Heart Device Study ↗
Via Benzinga
News headline image
What is Considered a Good Stock Dividend? 2 Healthcare Stocks That Fit the Bill. ↗
Via The Motley Fool
Topics Bonds
News headline image
Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium
From Johnson & Johnson
Via Business Wire
News headline image
Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut ↗
Via MarketBeat
News headline image
Johnson & Johnson Is A Resilient Blue-Chip Stock And It Just Hit New All-Time Highs ↗
Via Talk Markets

Frequently Asked Questions

Is Johnson & Johnson publicly traded?
Yes, Johnson & Johnson is publicly traded.
What exchange does Johnson & Johnson trade on?
Johnson & Johnson trades on the New York Stock Exchange
What is the ticker symbol for Johnson & Johnson?
The ticker symbol for Johnson & Johnson is JNJ on the New York Stock Exchange
What is the current price of Johnson & Johnson?
The current price of Johnson & Johnson is 241.60
When was Johnson & Johnson last traded?
The last trade of Johnson & Johnson was at 02/20/26 10:43 AM ET
What is the market capitalization of Johnson & Johnson?
The market capitalization of Johnson & Johnson is 635.10B
How many shares of Johnson & Johnson are outstanding?
Johnson & Johnson has 635B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.